Case Report: Hematologic Recovery Following Stereotactic Ablative Radiotherapy in a Patient With Early-Stage Non-Small Cell Lung Cancer and Paraneoplastic Myelofibrosis

Lindsey Sloan; Rakhi P Naik; Kavita Umrau; Rena Ruiyu Xian; Kristen A Marrone; Khinh Ranh Voong

doi:10.3389/fonc.2022.842620

Case Report: Hematologic Recovery Following Stereotactic Ablative Radiotherapy in a Patient With Early-Stage Non-Small Cell Lung Cancer and Paraneoplastic Myelofibrosis

Front Oncol. 2022 Feb 24:12:842620. doi: 10.3389/fonc.2022.842620. eCollection 2022.

Authors

Lindsey Sloan^{1

2}, Rakhi P Naik³, Kavita Umrau⁴, Rena Ruiyu Xian⁴, Kristen A Marrone⁵, Khinh Ranh Voong²

Affiliations

¹ Department of Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN, United States.
² Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins School of Medicine, Baltimore, MD, United States.
³ Department of Hematology, Johns Hopkins School of Medicine, Baltimore, MD, United States.
⁴ Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, United States.
⁵ Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, United States.

Abstract

Herein, we report the first case presentation of paraneoplastic myelofibrosis associated with cancer. Paraneoplastic syndromes occur in some patients with thoracic malignancies; however, myelofibrosis is not commonly seen in non-small cell lung cancer (NSCLC). We report a case of myelofibrosis in a patient with a new diagnosis of NSCLC that resolved after stereotactic ablative radiotherapy (SABR). In conclusion, NSCLC may evoke unexpected systemic effects that resolve with treatment.

Keywords: NSCLC; SAbR; case; paraneoplastic; report.

Publication types

Case Reports